Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early IVIG for COVID-19-associated ARDS requiring invasive mechanical ventilation
2020-001570-30Phase 3Completed
- Sponsor
- GHU Paris psychiatrie & neurosciences
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of Human normal immunoglobulin G in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by GHU Paris psychiatrie & neurosciences. Primary endpoint: Ventilator-free survival through day 28. Started Apr 2020; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-001570-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001570-30.